Evidence map›Paper›PMID 21879292›Full record

ArticleInternational journal of hematology2011

Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia.

Kotaro Arita, Takeshi Kondo, Junichi Sugita, Akio Shigematsu, Souichi Shiratori, Kentaro Wakasa, Atsushi Yasumoto, Makoto Ibata, Yusuke Shono, Misato Kikuchi and 8 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Kotaro AritaStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan. arita-tym@umin.ac.jp.
Takeshi KondoStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Junichi SugitaStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Akio ShigematsuStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Souichi ShiratoriStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Kentaro WakasaStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Atsushi YasumotoStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Makoto IbataStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Yusuke ShonoStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Misato KikuchiStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Hideki GotoStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Yukari TakedaStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Mutsumi TakahataStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Naoko KatoStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Mitsufumi NishioStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Shuichi OtaStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Junji TanakaStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Masahiro ImamuraStem Cell Transplantation Center, Hokkaido University Hospital, Sapporo, Japan.
Hokkaido University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for refractory acute lymphoblastic leukemia (ALL) is very poor. To improve survival rates, we attempted to intensify the conditioning regimen with daunorubicin, vincristine, prednisolone, medium-dose etoposide, cyclophosphamide, and total body irradiation (DNR/VCR/PSL plus medium-dose VP/CY/TBI). Four patients in relapse or induction failure of B-precursor ALL without other complications underwent allogeneic HSCT. Initially, chemotherapy comprising DNR 60 mg/m(2) for 3 days, VCR 1.4 mg/m(2) for 1 day, and PSL 60 mg/m(2) for 3 days was administered, which was followed by medium-dose VP/CY/TBI; some modifications were made for individual patients. All patients achieved engraftment and complete remission after HSCT. Regimen-related toxicities were tolerable and no patient died within 100 days. Two patients were alive without disease on days 563 and 1,055. The third patient relapsed on day 951, while the fourth died on day 179 without disease. Our results indicate that intensified myeloablative HSCT should be considered for patients with refractory ALL.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleGraft vs Host DiseaseHumansMalePrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionTransplantation, HomologousTreatment OutcomeWhole-Body IrradiationYoung Adult

Identifiers

PMID21879292
OpenAlexW1986221562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.